PI3K inhibitors in thrombosis and cardiovascular disease

被引:65
|
作者
Durrant, Tom N. [1 ]
Hers, Ingeborg [2 ]
机构
[1] Univ Oxford, Dept Chem, Oxford OX1 3QZ, England
[2] Sch Physiol Pharmacol & Neurosci, Biomed Sci Bldg,Univ Walk, Bristol BS8 1TD, Avon, England
来源
CLINICAL AND TRANSLATIONAL MEDICINE | 2020年 / 9卷 / 01期
关键词
Cardiovascular disease; Thrombosis; Platelets; Phosphoinositide; 3-kinase; PI3K; Phosphoinositides; Cellular signalling; II PHOSPHOINOSITIDE 3-KINASE; REGULATES PLATELET ACTIVATION; PHOSPHATIDYLINOSITOL 3,4,5-TRISPHOSPHATE; PI3K-GAMMA INHIBITION; P110-ALPHA ISOFORM; P110-BETA SUBUNIT; CRYSTAL-STRUCTURE; P2Y(12) RECEPTOR; DOSE-ESCALATION; CELL-MIGRATION;
D O I
10.1186/s40169-020-0261-6
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Phosphoinositide 3-kinases (PI3Ks) are lipid kinases that regulate important intracellular signalling and vesicle trafficking events via the generation of 3-phosphoinositides. Comprising eight core isoforms across three classes, the PI3K family displays broad expression and function throughout mammalian tissues, and the (patho)physiological roles of these enzymes in the cardiovascular system present the PI3Ks as potential therapeutic targets in settings such as thrombosis, atherosclerosis and heart failure. This review will discuss the PI3K enzymes and their roles in cardiovascular physiology and disease, with a particular focus on platelet function and thrombosis. The current progress and future potential of targeting the PI3K enzymes for therapeutic benefit in cardiovascular disease will be considered, while the challenges of developing drugs against these master cellular regulators will be discussed.
引用
收藏
页数:21
相关论文
共 50 条
  • [31] PI3K pathway inhibitors approach junction
    Holmes, David
    NATURE REVIEWS DRUG DISCOVERY, 2011, 10 (08) : 563 - 565
  • [32] Development and safety of PI3K inhibitors in cancer
    Yu, Miaomiao
    Chen, Jiajia
    Xu, Zhifei
    Yang, Bo
    He, Qiaojun
    Luo, Peihua
    Yan, Hao
    Yang, Xiaochun
    ARCHIVES OF TOXICOLOGY, 2023, 97 (03) : 635 - 650
  • [33] PI3K pathway inhibitors approach junction
    David Holmes
    Nature Reviews Drug Discovery, 2011, 10 : 563 - 564
  • [34] Inhibitors of PI3Kβ as Potential Treatment for Cancer
    Abdel-Magid, Ahmed F.
    ACS MEDICINAL CHEMISTRY LETTERS, 2013, 4 (09): : 815 - 816
  • [35] Is There Still a Role for PI3K Inhibitors in CLL?
    Flinn, Ian W.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2023, 21 (04) : 192 - 194
  • [36] Discovery and optimization of pyrimidone PI3Kβ inhibitors
    Halley, Frank
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2013, 245
  • [37] PI3K inhibitors: review and new strategies
    Zhang, Mingzhen
    Jang, Hyunbum
    Nussinov, Ruth
    CHEMICAL SCIENCE, 2020, 11 (23) : 5855 - 5865
  • [38] The Role of PI3kγ and PI3kΔ in Alloimmunity
    Uehara, M.
    Jamil, A.
    Solhjou, Z.
    McGrath, M.
    Banouni, N.
    Evans, C.
    Dinitto, J.
    Winkler, D.
    Abdi, R.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2016, 16 : 325 - 325
  • [39] PI3K Inhibitors in Breast Cancer Therapy
    Ellis, Haley
    Ma, Cynthia X.
    CURRENT ONCOLOGY REPORTS, 2019, 21 (12)
  • [40] PI3K Inhibitors in Breast Cancer Therapy
    Haley Ellis
    Cynthia X. Ma
    Current Oncology Reports, 2019, 21